United States Knee Implant Market By Analysis of Major Industry Segments 2016 - 2024

According to the research study, the U.S. market for knee implant offered an opportunity worth US$4.3 bn in 2015. Expanding at a CAGR of 5.30% during the period from 2016 to 2024, the market is projected to reach US$7.0 bn by the end of the forecast period. Hospitals demand a higher number of knee implants than other end users in the U.S. and are expected to remain doing so over the forthcoming years.

The leading implant manufacturers enjoy a broad presence across the U.S. Their comprehensive product portfolios and cross-selling strategies have ensured their dominance over this market in the last few years. However, over the forthcoming years, these players are expected to focus on new product launches in order to strengthen their presence in the U.S. market for knee implants.

Obtain Report Details @
http://www.transparencymarketresearch.com/us-knee-implant-market.html

Dominated by Johnson & Johnson, Zimmer Biomet Holdings Inc., Smith & Nephew, and Stryker Corp., the U.S. knee implant market demonstrates a highly consolidated and competitive landscape, states a new research report by Transparency Market Research (TMR). With a share of nearly 85%, these players ran almost the whole market in 2015.

Midwest Region to Maintain Lead through 2024

In this research study, the U.S. market for knee implants has also been studied on the basis of its geographical presence. The Pacific region, the Mountain region, the South Central region, the Midwest region, the South Atlantic region, and the North East region have been considered as the prime geographical subdivisions of the U.S. knee implant market. The Midwest region has acquired the leading position in this market. The availability of numerous ambulatory surgical centers present in this region is the key factor behind this rise. The augmenting adoption of new technologies is also supporting this geographical segment in maintaining its lead.

The market for knee implants in the Midwest region is likely to remain dominant throughout the forecast period. The presence of a large pool of knee implant manufacturers and a massive and effective distribution channel are expected to aid this regional market to remain leading over the next few years.

Increasing Geriatric Population to Boost Demand for Knee Implants in U.S.

“The ever-increasing geriatric population is the key factor behind the rise of the U.S. knee implant market,” states an analyst at TMR. With the increasing age, cartilages become prone to strain, owing to less water content, leading to arthritis and cushioning at the joints, which requires knee replacement procedure. Moreover, other connective tissues, such as ligaments attached to the bones, begin becoming less flexible and more constrained, which also add to the need for these procedures. Thus, the increase in the geriatric population in the U.S. is reflecting positively on the U.S. market for knee implants.

Apart from this, the rising incidence of accidental injuries, surging prevalence of chronic rheumatic conditions, growing obese population, and the increasing adoption of advanced knee products and procedures are also propelling the demand for knee implants in this country.

On the other hand, strict regulations implemented by the FDA on knee implant products, knee implant product recall by the FDA, and the rising awareness of non-surgical alternative treatment among consumers may hamper the growth of this market to some extent in the near future, states the report.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19649

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Autologous Matrix-induced Chondrogenesis Market to be worth US$186.38 mn by 2024

The leading players operating in the global autologous matrix-induced chondrogenesis (AMIC) market are working towards strengthening their foothold in emerging economies such as Brazil, India, China, Mexico, and South Africa. The strategy to expand to these countries is expected to benefit the companies as they will be able to employ cheaper skilled labor, thereby bringing down the costs of their products. Furthermore, the burgeoning medical tourism industry in these countries is also expected to augment the demand for AMIC products and procedures. The leading players in the global market as of 2015 were Geistlich Pharma AG, Zimmer Biomet Holdings, and Smith & Nephew plc. Collectively, these companies held a share of 47% in the overall market in 2015.

The global autologous matrix-induced chondrogenesis is expected to be worth US$186.38 mn by 2024 from US$89.71 mn in 2015. During the forecast years of 2016 and 2024, the global market is projected to expand at a CAGR of 8.6%.

Obtain Report Details @
http://www.transparencymarketresearch.com/autologous-matrix-induced-chondrogenesis-market.html

Collagen to Lead with Extensive Usage in Tissue Engineering Applications

On the basis of material, the global AMIC market is segmented into hyaluronic acid, collagen, polyethylene glycol (PEG), and poly lactic-co-glycolic acid (PGLA). Of these, collagen dominates the global market. However, the segment is projected witness a minor slip during the forecast period. Despite factors challenging the collagen segment, it is poised to acquire a share of 49.9% in the overall market by the end of 2024. The extensive usage of collagen for tissue engineering applications is estimated to give the segment a major boost in the coming years.

In terms of geography, the global AMIC market is fragmented into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Out of all these regional segments, North America is projected to lead the global market throughout the forecast period. Between 2016 and 2024, the North America AMIC market is estimated to expand at a CAGR of 8.3%. This regional market is likely to be driven by the growing pool of geriatrics.

Sports Injuries to Offer Lucrative Ground for AMIC Products and Procedures

The mounting demand for minimally invasive surgeries is expected to spike the sales of AMIC materials and products in the coming few years. AMIC is a biological treatment that uses bi-layer collagen via microfracture surgery to repair articular cartilage damage. This single-step procedure has allowed several end users to opt for the convenient solution of a minimally invasive surgery to overcome bone and joint disorders. The increasing pool of the aging population that is susceptible to such conditions is projected to provide a substantial boost to the overall market in the coming years.

The market is also likely to be driven by the increasing number of sports injuries are participation in various types of sports continues to be on the rise. The growing popularity of adventurous sports among the younger population is expected to fuel the uptake of AMIC material and products to treat sports injuries. The fast recovery rate of the AMIC has also benefited the global market as it considerably reduces the risk of unnecessary complications.

Lack of Insurance Policies for AMIC Procedures to Dampen Market Spirits

The steadfast demand for AMIC is being deterred by the inefficient reimbursement system in developing countries such as Brazil, Australia, and India.  Several health insurance companies do not insure AMIC products or procedures, which has discouraged many patients from opting for it. Furthermore, lack of clinical data supporting the advantages and the long-term benefits or consequences of using AMIC products and procedures is also restraining the growth of the global market.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19289

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Mass Spectrometer Market Analysis by Segments, Size and Forecast 2016 - 2024

According to a research publication released by Transparency Market Research, the global mass spectrometry market will be showing a strong sense of competitive rivalry, especially among the leading entities. The overall number of players in the global mass spectrometry market is small and their relative market share is very large. Their established presence is expected to stifle the entry of new players into the global mass spectrometry market. The production of new mass spectrometry equipment is, however, being contended by the growing availability of refurbished ones. This applies more so to the developing economies where the cost of purchasing new equipment can be too high.

With a highly consolidated nature, the global mass spectrometry market was led by Agilent Technologies, Thermo Fisher Scientific, Inc., and Shimadzu Corporation in 2015. Their collective share in the market’s value for the year was close to 49%, revealing a very low scope of growth for smaller players at the current rate.

Browse Market Research Report @
http://www.transparencymarketresearch.com/mass-spectrometer-market.html
 
The global mass spectrometry market is expected to reach US$9.99 bn by the end of 2024, after expanding at a healthy CAGR of 8.1% within a forecast period from 2016 to 2024. The market’s value was calculated to reach US$5.35 bn at the end of 2016. North America is expected to generate a massive revenue for the global mass spectrometry market owing to its booming biotech industry.mass spectrometer market

Advancements in Mass Spectrometry Open New Doors

“What drives the global mass spectrometry market at the present moment is the original scope of application of these systems, coupled with the new possibilities that are entering the market simultaneously. One of the more recent examples of technological advancements in mass spectrometry is the adoption of matrix-associated laser desorption ionization imaging mass spectrometry, or MALDI-IMS. This system allows for the examination and analysis of tissues from a diagnostic perspective and thus reduces the overall time required for complete analysis of the sample. Another recent development is the high-resolution accurate mass system, which can detect as well as deliver simultaneously a higher resolution of the full product ion spectrum and mass accuracy. These systems are expected to usher in a new era of mass spectrometry,” states a TMR analyst.

The global mass spectrometry market is also being driven by the growing use of these equipment in the industries of pharmaceuticals, life sciences, and other clinical analytics. On the competitive side, the market is being favored in overall growth by the significant mergers and acquisitions that have occurred over the past decade, which includes the acquisition of Active Spectrum, Inc., by Bruker.

High Equipment Costs Reduce Production Rates

One of the key restraints affecting the global mass spectrometry market currently, is the high cost of it research and development it takes to generate newer technologies in the market. This not only severely limits the entrance of new players into the market, but also creates a sizeable barrier of pricing for several buyers from emerging economies. Their reluctance to buy newer technologies is leading to the growth of refurbished mass spectrometry equipment, which not only reduces the overall profits that key players in the market make, but also reduces the investments they can make into advanced development of equipment.

“Despite the given restraints, research and development is still likely to be the way to go for the global mass spectrometry market, when it comes to improving the scope of opportunities in the future. The developments in continuous flow technologies have, for instance, created the space for new devices to enter the market that are significantly more efficient than their predecessors. The players from the global mass spectrometry market can also find a greater scope of opportunities in the emerging economies from Asia Pacific and Latin America – specifically Brazil – to improve their sales figures,” adds the analyst.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=18917

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Biodegradable Stents Market By Analysis of Major Industry Segments 2016 - 2024

The competitive landscape in the global biodegradable stents market is quite consolidated as major players in the market hold a massive chunk. In 2015, Abbott Laboratories, Boston Scientific, Inc., and Biotronik led the pack with a 61.5% share in the global market. The unwavering focus of these companies on expanding their business in newer territories has enabled them to dominate the global market. In the coming years, the players are expected to invest in advanced and sophisticated products to offer better products to the overall healthcare industry.

According to the research report, the global biodegradable stents market is anticipated to be worth US$1.7 bn by 2024 as compared to US$18 mn in 2015. During the forecast years of 2016 and 2024, the global market is expected to expand at a CAGR of 30.1%.

Obtain Report Details @
http://www.transparencymarketresearch.com/biodegradable-stents-market.html

Europe Emerges as Leading Regional Market Backed by German Demand

The two types of stents available in the global biodegradable stents market are coronary artery stents and peripheral artery stents. Of these, the coronary artery stents are expected to progress at a CAGR of 30.9% during the forecast period. The high incidence of coronary artery diseases is expected to drive this segment in the coming years.

In terms of regions the global market is divided into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. The report indicates that Europe will emerge as the dominant segment in the global market in the coming years. This regional market is expected to surge at a CAGR of 27.2% during the forecast period. Germany will lead the Europe biodegradable stents market in the coming few years.

Rise in Cardiovascular Diseases Spikes Demand for Biodegradable Stents

The Centers of Disease Control and Prevention (CDC) states that coronary artery diseases are responsible for 370,000 deaths across the U.S. every years. The global biodegradable stents market has been growing against the backdrop of high incidence of cardiovascular diseases, which are related to coronary artery diseases. The market is also being driven by the high prevalence of chronic conditions and rising geriatric population, which is prone to cardiovascular disorders. “The growing preference for stenting procedures for treating coronary artery diseases over bypass surgeries is also anticipated to boost the sales in the global market,” estimates the lead author of this research report. This trend is likely to be a key trend in the market as stenting reduces complications, assures better success rate, fastens recovery time, and costs less.

Bare metal stents (BMS) and drug eluting stents (DES) continue to remain in the artery long after it has eluted the drug. This can lead to thrombosis, in-stent restenosis, and other complications, which can require surgical removal of the stent. Thus, use of biodegradable stents are remarkable safer as they get completely absorbed in the artery soon after the drug is eluted. This factor has won the biodegradable stents incredible traction over the past few years.

Unaffordability of Biodegradable Stents Dissuades Patients

Although the global biodegradable stents has a noteworthy CAGR, the market is likely to suffer due to the high cost of the products. Thus, the advantages of biodegradable stents are getting stymied due to their unaffordability. The premium pricing of these stents is expected to restrain the overall market’s growth in the coming years. Furthermore, the slow adoption rate of these stents in regions and countries where medical awareness is relatively low is also hampering the progress of the global market.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=12464

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Competitive Landscape for Global Psoriasis Treatment Market by Segments - 2024

The global market for psoriasis treatment demonstrates a highly competitive landscape, finds a research report by Transparency Market Research (TMR). With the rising investments in research and development in the field of psoriasis treatment, the rivalry between the leading players, such as Biogen, LEO Pharma, AbbVie, AstraZeneca, and Pfizer, is likely to intensify in the near future. 

According to TMR’s estimations, the opportunity in the global market for psoriasis treatment, which was worth US$7.8 bn in 2015, is projected to expand at a CAGR of 5.10% during the period for 2016 to 2024 and attain a value of US$12.1 bn by the end of the forecast period. TNF inhibitors have emerged as the most demanded product in this market. Researchers expect the demand to increase further and result in a more than 47% possession of this segment in the overall market by 2024. 

Obtain Report Details @
http://www.transparencymarketresearch.com/psoriasis-treatment-market.html

North America to Remain on Top 

In this research study, the global market for psoriasis treatment has also been analyzed on the basis of geography. As per the report, Latin America, North America, Europe, Middle East and Africa, and Asia Pacific are considered as the prime regional market for psoriasis treatment. North America, which has been identified as the key contributor to the global market, is likely to remain gaining significantly from the substantial rise in the pool of patients suffering from psoriasis over the forecast period. The increased demand for psoriasis treatment products is likely to reflect positively on this regional market in the forthcoming years. 

Europe, which stood second in 2015, is, however, expected to witness a decline in its share by 2024, owing to the anticipated introduction of biosimilars over the next few years. On the other hand, Latin America and Asia Pacific are projected to witness tremendous growth in their respective markets over the forthcoming years. The growing awareness about psoriasis disease and its treatment among people residing in emerging economies, such as China and India, through a number of campaigns run by the governments and healthcare organizations is anticipated to boost the Asia Pacific market for psoriasis treatment considerably in the years to come, notes the study. 

Alarming Rise in Prevalence of Psoriasis to Prompt Drugmakers to Increase Production Capacity 

“The alarming rise in the prevalence of psoriasis is the key driving force behind the significant growth of the global psoriasis treatment market,” states an analyst at TMR. According to the WHO, between 1979 and 2008, the prevalence of psoriasis, globally, increase from 4.8% to 11.4%. The trend looks undying in the near future and is encouraging the leading drugmakers to increase their production capacities, leading to a remarkable surge in this market. The FDA approval of new biologics is also prompting them to invest heavily in research and development of psoriasis therapies. 

In addition to this, the rising access to treatment in developing economies and the presence of a robust pipeline points towards a thriving future of the global psoriasis treatment market in the years to come. However, the loss of response to current therapies and the high price of biologics may restrict the growth of this market in the near future, states the research report. 

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17960

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Outlook for Diabetic Neuropathy Market By Key Trends and Analysis 2025

Global Diabetic Neuropathy Market: Snapshot

A handful of international and local manufacturers with limited shares dominate the global diabetic neuropathy market. This makes the competitive landscape semi-consolidated in nature. The competition among them is intense with most spending time and money on research and development of more effective neuropathy drugs.

The global diabetic neuropathy market is being primarily driven by changing lifestyles which has mostly resulted in unhealthy dietary habits and patterns. As per WHO, about 422 were afflicted by diabetes in 2014. Apart from that, other growth drivers in the market are the approval of novel drugs to treat neuropathic pain and supportive reimbursement policies.

A report by Transparency Market Research, forecasts the global diabetic neuropathy market to become worth US$5.718 bn by 2024 from US$ 3.6 bn in 2016 by rising at a steady CAGR of 5.4% between 2017 and 2025.

Obtain Report Details @
http://www.transparencymarketresearch.com/diabetic-neuropathy-market.html

Drugs administered to treat neuropathic pain, however, so far have had only limited success in terms of pain relief. This coupled with erroneous diagnosis or selection of treatment and side effects and rising cost of diabetic neuropathy treatment drugs are posing a hindrance to the market for diabetic neuropathy market.

Peripheral Neuropathy to Retain its Dominant Share by Clocking Maximum Growth

Peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy are the prominent disorders in the global diabetic neuropathy market. Peripheral neuropathy, of them, accounts for almost half the share in the market at present. In the near future it is predicted to grow its share marginally by surpassing all other segments in terms of growth rate. The report by TMR predicts the segment to clock a 5.7% CAGR from 2017 to 2025 because of the high prevalence of diabetic neuropathy.

Proximal neuropathy follows peripheral neuropathy when it comes to market share in the global diabetic neuropathy market. This is because proximal diabetic neuropathy is the most commonly found disorder in type 2 diabetes. The segment was worth US$885.6 mn in 2016 and will likely rise to US$1.405 mn by 2025 by expanding at a CAGR of 5.4% from 2017 to 2025.

Major Players Target North America Market Having Large Patient Pool

Key regional segments in the global diabetic neuropathy market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among them, North America accounted for a market leading share of 34.9% in 2016. This is mainly on account of the large pool of patients who have been diagnosed and the expensiveness of therapy. In fact, keen companies are eyeing the market in U.S. in the region to up sales and revenues. The market in North America was worth US$1.071 bn in 2016 and rising at 5.3% CAGR between 2017 and 2025, it is slated to become worth US$1.68 bn by 2025.

Europe trails North America in the global diabetic neuropathy market in terms of size. Its market has been mostly driven by the rising occurrence of diabetic neuropathy and a growing pool of elderly, particularly in countries of Italy, Germany, France, and the U.K. In terms of growth rate, however, the market is Asia Pacific is predicted to outshine all others. Powered primarily by China, Asia Pacific will likely clock a CAGR of 6.7% on account of the growing number of healthcare awareness programs, hospitals equipped with radiology devices to treat diabetic neuropathy, and a large pool of patients.

Some of the key names operating in the market are Pfizer, Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, Lupin Limited, Depomed, Inc., Glenmark Pharmaceuticals Ltd, and Arbor Pharmaceuticals, LLC.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2199

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Neurological Disorder Drugs Market - Europe Industry Volume and Region Analysis - 2024

The Europe neurological disorder drugs market is remarkably consolidated due to presence of small players who hold a significant share in the overall market. Transparency Market Research has observed Merck & Co., Bayer AG, Astra Zeneca, Novartis AG, and GlaxoSmithKline plc. These top five players held a whopping share of 60.5% in the overall market in 2015.  “These players are expected to focus on expanding their geographical reach and strengthening their pipeline with multiple drug class,” states the lead author of this research report.                                     

According to the research report, the Europe neurological disorder drugs market was valued at US$18.3 bn in 2015 and is expected to reach a valuation of US$32.0 bn by the end of 2024. During the forecast period of 2016 and 2024, the global market is projected to expand at CAGR of 6.4%.

Obtain Report Details @
http://www.transparencymarketresearch.com/europe-neurological-disorder-drugs-market.html

Germany Exhibits CAGR of 6.8% during Forecast Period in Overall Market

The Europe neurological disorder drug market caters to a wide range of diseases. However, analysts anticipate that the cerebrovascular disease segment will progress at a CAGR of 6.9% during the forecast period. On the basis of countries, the market is divided into Germany, France, Italy, Spain, UK, Russia, Switzerland, Netherlands, Poland, and Rest of Europe. Of these, Germany is projected to surpass all others as the country’s neurological disorder drugs is expected to rise at a CAGR of 6.8% between 2016 and 2024.

Aging Population Offers Tremendous Scope for Growth

The remarkable rise in brain-altering diseases has prompted several pharmaceutical companies to tap into the potential market of neurological disorder drugs. The market is expected to thrive due to the rise in investments in research and development of innovative drugs being designed to manage disorders such as Alzheimer’s disease, epilepsy, Parkinson’s disease, cerebrovascular disease, and multiple sclerosis among others. The spike in the geriatric pool of Europe is also a steady factor supporting the growth of the overall market. Growing number of clinical trials are also projected to provide the global market adequate boost in the coming years.

Out of the various drugs for a range of neurological disorders, the cerebrovascular diseases held a dominant share in the global market. Analysts project that this segment will continue to show tremendous progress in the coming years due to growing number patients with complains such as strokes, migraine, and headaches. Statistics show that about 80% of the people in EU5 countries deal with strokes, which is a major part of the cerebrovascular disease. The steady change in the nature of neurological disorders is also projected to play a significant part in the development of the Europe neurological disorder drugs market.

Stringent Regulations for Prescribing Sedatives Hamper Market Growth

The treatment of neurological disorders is exorbitant as it comes with several additional costs of antiepileptic, anticholinergic and hypnotic and sedative drugs. The high cost of research and development has also slowed down the drug development. Furthermore, decline in innovation has resulted in mature product portfolios, which has limited the market in several ways. All of these factors are expected to hamper the growth of the Europe neurological disorder drugs market in the coming years. In addition, the stifling regulations about prescribing sedatives are also expected to restrict market’s growth in the coming few years.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17567

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.